CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 320 enrolled
Drug / intervention
NGM621 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04465955
NCT04465955Phase 2Completed
CompareCT.gov

A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NGM Biopharmaceuticals, Inc·interventional·Posted Jul 10, 2020·Updated Jul 1, 2025

In Brief

A Phase 2 clinical trial evaluating NGM621 and Sham Comparator for Geographic Atrophy. Completed, enrolled 320 participants across 65 sites.

Detailed Summary

This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeographic Atrophy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 10, 2020
Enrollment StartJul 22, 2020
Primary CompletionAug 16, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.0 years ago

Interventions

NGM621biological

NGM621 Dose 1

NGM621biological

NGM621 Dose 2

Sham Comparatorother

Sham Comparator